Lu AG13909
Alternative Names: Lu-AG13909Latest Information Update: 04 Jul 2024
Price :
$50 *
At a glance
- Originator Lundbeck A/S
- Class Monoclonal antibodies
- Mechanism of Action Corticotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pituitary ACTH hypersecretion
- Phase I Congenital adrenal hyperplasia
Most Recent Events
- 04 Jul 2024 Lundbeck A/S plans a phase II trial in Pituitary ACTH hypersecretion (IV,SC) in June 2024 (NCT06471829)
- 19 Jun 2024 Phase-II clinical trials in Pituitary ACTH Hypersecretion in Georgia (SC, IV) (NCT06471829)
- 01 Jun 2024 Pharmacodynamics and adverse event data from a preclinical trial in Congenital adrenal hyperplasia presented at the 106th Annual Meeting of the Endocrine Society (ENDO-2024)